Orthocell posts record $279,000 U.S. sales in October
Key points
- Orthocell generated $279,000 in monthly revenue after selling 92 units of its nerve repair product, Remplir, in the U.S. during October.
- The October sales performance marks an 84% uplift compared to average monthly sales of 50 units in the first quarter of FY27.
- Growth was driven by increasing surgeon adoption, repeat utilisation, expanding distributor networks, and broader hospital access across key U.S. markets.
Orthocell (ASX:OCC) reported $279,000 in U.S. revenue for October after selling 92 units of its nerve repair product, Remplir.
The monthly result represents an 84% increase over the company's Q1 FY27 average of 50 units per month.
"October represents an important milestone in Orthocell’s U.S. commercialisation, with the groundwork laid over the past 12 months now translating into tangible revenue," said Orthocell CEO and MD Paul Anderson.
The company noted that commercial momentum was supported by hospital access approvals through Value Assessment Committees, alongside growing distributor representative activity.
Orthocell stated that the performance provides evidence of strengthening U.S. commercial traction to support continued revenue growth.
Following the announcement, the Orthocell share price was unchanged at $0.57.
The Australian medical technology firm focuses on developing regenerative medicine products to restore damaged tissue and nerve function.
Frequently asked questions
More from Australia
Investor backs Gold Hydrogen with funding
Rimfire Pacific resolves legal dispute with Golden Plains Resources
Australia reports 5.1% rise in September dwellings
ASIC finds super trustees failed at complaints handling
Neuren Pharmaceuticals gains FDA orphan drug status for brain injury treatment
Golden Horse Minerals to spin out Sorrel Copper Project
